Salix Pharmaceuticals

Piper Jaffray, which raised its PT on shares of Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), is providing some color on the stock. “Yesterday, Salix announced that the U.S. Patent and Trademark Office issued three additional patents for Xifaxan (rifaximin),” Piper Jaffray writes. “We believe the...

Piper Jaffray has raised the price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $39 to $42 and maintains its Overweight rating.

According to Piper Jaffray, Salix Pharmaceuticals (NASDAQ: SLXP) is not alarmed by the letter to the NEJM. Piper Jaffray reported that the April 14, 2011 issue of the New England Journal of Medicine (NEJM) featured two letters to the editor expressing misgivings regarding Xifaxan in non-...

Jefferies is out with its report today on Salix Pharmaceuticals (NASDAQ: SLXP), maintaining Buy. In a note to clients, Jefferies writes, "The success of SLXP hinges on Xifaxan and all signs indicate that usage will continue to go up – despite no formal IBS approval. Our $42 target price is derived...

Piper Jaffray has lowered the price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $60 to $39 and maintains its Overweight rating.

Goldman Sachs is out with its report on Salix Pharmaceuticals (NASDAQ: SLXP), maintaining Buy. In a note to clients, Goldman Sachs writes, "We maintain our Buy rating and Conviction List membership on SLXP with shares offering a unique combination of significant growth, near-term catalysts, and M...

Piper Jaffray is out with its report today on Salix Pharmaceuticals (NASDAQ: SLXP), reiterating Overweight. In a note to clients, Piper Jaffray writes, "With strong sales growth, high Xifaxan gross margins (near 90% for the 550 mg dose), and moderate growth in R&D spend, we continue to see...

Yesterday, Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) announced the acquisition of worldwide rights (excluding Japan) to Progenics' Relistor (methylnaltrexone), Piper Jaffray reports. “A subcutaneous (SC) formulation is approved for the treatment of opioid-induced constipation (OIC) in patients...

Goldman Sachs initiates coverage on Salix Pharmaceuticals (NASDAQ: SLXP) with a Conviction Buy rating and a $58 price target. In a note to clients, Goldman Sachs views SLXP as, "the most compelling small-cap growth story across our Healthcare coverage. New indications for Xifaxan, its gut selective...

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) will not receive a "74-day letter" from the FDA relating to the NDA for Xifaxan, meaning there are no major deficiencies in the filing, according to Piper Jaffray, meaning the review of the filing is progressing smoothly and expected to be in action as of...

Oppenheimer analysts John Newman and Christopher Holterhoff maintained their Outperform rating and price target of $40 for shares of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP). The analysts said that they expect an FDA decision on XIFAXAN in HE by March 24 2010, with a launch date by late May and...

Shares of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) skyrocketted today, a day after the Gastrointestinal Drugs Advisory Committee of the FDA voted 14 to 4 in favor of the use of the company's XIFAXAN (rifaximin) 550 mg Tablets for the maintenance of remission of hepatic encephalopathy. BMO...